Epithalon- und Telomerlänge: Überprüfung von Forschungsdaten
Veröffentlicht: 2025-09-28 08:06:00 | PEPTEX Research
Telomeres sit at the ends of every chromosome like protective caps. Each time a cell divides, these caps shorten. When they become critically short, the cell enters senescence — it stops dividing and begins to deteriorate. This process is one of the most well-documented drivers of biological aging.
The question that researchers at the Saint Petersburg Institute of Bioregulation and Gerontology have spent decades trying to answer: can a short synthetic peptide reverse that shortening? Their candidate — Epithalon (Ala-Glu-Asp-Gly), also referred to as Epitalon — has accumulated a body of experimental data that deserves serious attention.
What Are Telomeres and Why Do They Shorten?
Telomeres consist of repetitive TTAGGG nucleotide sequences bound by a protein complex called shelterin. In human somatic cells, telomere length at birth averages 8,000–13,000 base pairs. With each cell division cycle, 50–200 base pairs are lost due to the "end-replication problem" — DNA polymerase cannot fully copy the lagging strand terminus.
An enzyme called telomerase can add TTAGGG repeats back to chromosome ends, but its expression is suppressed in most adult somatic cells. Cells with high turnover — stem cells, immune cells, germ cells — retain some telomerase activity, but it declines with age. The result is progressive telomere attrition: a molecular clock that limits cellular lifespan.
Leonard Hayflick demonstrated this limit in 1961 when he showed that human fibroblasts divide approximately 40–60 times before permanent growth arrest. Elizabeth Blackburn, Carol Greider, and Jack Szostak received the 2009 Nobel Prize for elucidating the mechanism: telomerase, telomere structure, and their role in chromosome protection.
Epithalon: From Pineal Gland Extract to Synthetic Tetrapeptide
The story of Epithalon begins with Vladimir Khavinson's work on Epithalamin — a polypeptide extract derived from bovine pineal glands. Throughout the 1980s and 1990s, Khavinson and colleagues at the Saint Petersburg Institute demonstrated that Epithalamin administration extended lifespan in multiple animal models and appeared to modulate neuroendocrine function.
The logical next step was isolation of the active sequence. Khavinson's group identified the tetrapeptide Ala-Glu-Asp-Gly as the minimal sequence responsible for the biological effects observed with the full extract. This synthetic version — Epithalon — offered advantages in reproducibility, purity, and standardized dosing that the crude extract could not match.
Khavinson holds patents related to the use of this peptide for telomerase activation and life extension research, and his group has published over 200 papers on peptide bioregulation, with Epithalon being the most extensively studied compound in their repertoire.
The Telomerase Activation Data
The landmark paper on Epithalon and telomerase was published in the Bulletin of Experimental Biology and Medicine (2003). Khavinson and Anisimov reported that Epithalon treatment of human fetal fibroblast cultures increased telomerase activity by a factor of 2.4 compared to untreated controls. This effect persisted for up to 6 months after the treatment course was completed.
The mechanism proposed involves Epithalon's interaction with the hTERT gene promoter — the catalytic subunit of human telomerase. The peptide appears to de-repress hTERT transcription, leading to increased production of functional telomerase enzyme. Unlike genetic manipulation of telomerase (which carries oncogenic risk), peptide-mediated activation appears to restore telomerase to physiologically normal levels rather than forcing overexpression.
In the same study, fibroblast cultures treated with Epithalon exceeded the Hayflick limit, reaching 44 passages compared to 34 passages in control cultures. The additional population doublings correlated with measurably longer telomeres in the treated cells.
Dose-Response Observations
Subsequent work examined different concentrations and treatment durations. The consistently effective range in cell culture studies was 20–200 nM. In animal models, subcutaneous administration at 0.1–1.0 mcg per mouse (approximately 5–50 mcg/kg) produced measurable effects on pineal function and melatonin synthesis within 5–10 days of daily administration.
Human protocols used in Khavinson's clinical observations typically involved 5–10 mg administered subcutaneously for 10–20 consecutive days, repeated every 4–6 months. These dosing parameters come from published case series rather than randomized controlled trials.
Lifespan Extension in Animal Models
Multiple rodent studies from Khavinson's group and independent laboratories provide the animal data context:
- CBA mice (Anisimov et al., 2001): Female CBA mice receiving Epithalamin starting at age 6 months showed a 12.3% increase in mean lifespan and a 25.8% increase in maximum lifespan compared to controls.
- SHR mice (Khavinson et al., 2000): Epithalon treatment beginning in middle age produced a 31% reduction in spontaneous tumor incidence alongside increased lifespan.
- Drosophila studies (Khavinson & Lezhava, 2000): Epithalon added to fruit fly medium extended mean lifespan by 11–16%, with activation of specific genes associated with longevity pathways.
- Rat retinal studies (Khavinson et al., 2002): Epithalon administration preserved retinal cell function in aging rats, correlating with maintained telomere length in retinal pigment epithelial cells.
It is worth noting that the most robust data comes from Khavinson's own research group. While these results have been presented at international gerontology conferences and published in indexed journals, independent replication from laboratories outside of Russia remains limited. This is a legitimate caveat that responsible consumers of this data should keep in mind.
Mechanism of Action: Beyond Telomerase
Epithalon's effects are not limited to telomerase activation. The published literature describes several parallel mechanisms:
Pineal Gland and Melatonin
Epithalon stimulates melatonin production in the pineal gland. In aging organisms, pineal calcification reduces melatonin output — a decline associated with disrupted circadian rhythms, reduced antioxidant defense, and impaired immune function. Khavinson's data shows that Epithalon can partially restore melatonin synthesis to levels typical of younger organisms.
Melatonin itself has documented effects on telomere biology. It activates SIRT1 (sirtuin 1), which protects telomeres from oxidative damage. The Epithalon-melatonin-SIRT1-telomere axis may represent a reinforcing feedback loop that amplifies the direct telomerase activation effect.
Antioxidant Defense
Oxidative stress accelerates telomere shortening. Reactive oxygen species (ROS) damage guanine-rich telomeric DNA preferentially — telomere sequences are roughly 7 times more susceptible to oxidative damage than the genomic average. Epithalon has been shown to upregulate superoxide dismutase (SOD) and glutathione peroxidase activity in tissue culture models, providing an indirect protective mechanism for telomere integrity.
Gene Expression Regulation
Khavinson's peptide bioregulation theory posits that short peptides interact with specific DNA sequences to modulate gene expression. For Epithalon, this interaction appears to involve histone modification and chromatin remodeling at the hTERT locus. The peptide does not alter DNA sequence — it modifies the epigenetic landscape that controls gene accessibility.
Practical Considerations for Research Peptides
For those following the research and considering Epithalon for their own investigation, several practical points from the published literature deserve attention.
Reconstitution and Storage
Epithalon is typically supplied as a lyophilized (freeze-dried) powder. It reconstitutes readily in bacteriostatic water. Once reconstituted, it should be stored at 2–8°C and used within 28 days. The lyophilized form is stable at room temperature for extended periods but benefits from refrigeration.
Administration Routes
Subcutaneous injection is the most commonly documented route in the literature. The tetrapeptide structure is susceptible to gastrointestinal proteases, making oral administration impractical without encapsulation technology. Intranasal delivery has been explored in some studies but lacks the pharmacokinetic data available for subcutaneous routes.
Cycling Protocols in Published Research
The research protocols consistently use cyclical administration: 10–20 days of daily injections followed by a break of 4–6 months. Khavinson's rationale for cycling involves allowing endogenous regulatory pathways to reset — the peptide appears to "prime" telomerase expression rather than maintaining it through continuous exposure. The observation that telomerase activation persists for months after a treatment course supports this approach.
How Epithalon Compares to Other Telomerase-Related Compounds
Epithalon is not the only compound studied for telomerase activation. A comparative perspective helps frame its position in the research landscape:
| Compound | Mechanism | Evidence Level | Key Consideration |
|---|---|---|---|
| Epithalon | hTERT de-repression | Cell culture + animal models + case series | Extensive dataset from Khavinson group |
| TA-65 (Cycloastragenol) | Telomerase activation via astragaloside | Cell cultur... PEPTEX liefert nach Deutschland, Österreich und in die Schweiz — schneller Versand, laborgeprüfte Qualität, kostenlose Lieferung ab 150 €. Weiterlesen: Epithalon- und Telomerlänge: Überprüfung von ForschungsdatenArticlesВведите корректный email
Введите имя и фамилию
▾
Get in touchChoose how you'd like to reach us
or email us
🎁
Special offer for youEnter your email and get 15% off your first order 🪙 Оплата криптовалютойШаг 1 из 2 — выберите валюту
Dosage Calculator
1
Loading...
💬
SupportChoose a convenient way to contact us Проверка подлинностиВведите серийный код с упаковки
0
Задания
⏳
⏳
FAQ⏳
|
💬 Комментарии